Company Filing History:
Years Active: 2015-2016
Title: Sang-Ryeol Shim: Innovator in Monoclonal Antibody Research
Introduction
Sang-Ryeol Shim is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of human monoclonal antibodies. With a total of 3 patents to his name, his work is paving the way for advancements in cancer treatment.
Latest Patents
One of Sang-Ryeol Shim's latest patents focuses on a human monoclonal antibody that neutralizes vascular endothelial growth factor receptor. This invention relates specifically to human ScFv molecules that inhibit angiogenesis and can be used in cancer treatment. The disclosed monoclonal antibody demonstrates excellent neutralizing ability in living cells, outperforming commercially available antibodies against vascular endothelial growth factor receptor. It has shown effectiveness not only in humans but also in mice and rats, making it a valuable asset in anticancer studies.
Career Highlights
Sang-Ryeol Shim is currently associated with Pharmabcine Inc., where he continues to innovate in the field of antibody research. His work has garnered attention for its potential applications in treating various forms of cancer.
Collaborations
He has collaborated with notable colleagues, including Jin-San Yoo and Weon-Sup Lee, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Sang-Ryeol Shim's contributions to monoclonal antibody research are significant and impactful. His inventions hold promise for advancing cancer treatment and improving patient outcomes.